PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
Sumitomo Pharma sees the lack of an in-house diabetes pipeline as a major strategic challenge going forward, President and CEO Toru Kimura said at the company’s earnings briefing on January 30. While touting the firm’s sales strength and relationships with…
To read the full story
Related Article
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
- Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
May 14, 2025
BUSINESS
- Novo Nordisk Hints at GLP-1 Supply Restrictions to Curb Inappropriate Use
October 29, 2026
- Tatsumi Finds Nitrosamine in Migraine Drug; No Recall Planned
October 29, 2026
- Nxera Licenses Fabry Disease Drug from Idorsia
October 29, 2026
- Investment Firm Kopernik Lifts Kyorin Voting Stake Above 10%
October 29, 2026
- Leqembi Global Sales Climb to 61.5 Billion Yen in April-September: Eisai
October 29, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…